JP2022506956A5 - - Google Patents

Info

Publication number
JP2022506956A5
JP2022506956A5 JP2021525115A JP2021525115A JP2022506956A5 JP 2022506956 A5 JP2022506956 A5 JP 2022506956A5 JP 2021525115 A JP2021525115 A JP 2021525115A JP 2021525115 A JP2021525115 A JP 2021525115A JP 2022506956 A5 JP2022506956 A5 JP 2022506956A5
Authority
JP
Japan
Prior art keywords
lipid nanoparticles
nanoparticles according
approximately
nucleic acids
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506956A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/060582 external-priority patent/WO2020097540A1/en
Publication of JP2022506956A publication Critical patent/JP2022506956A/ja
Publication of JP2022506956A5 publication Critical patent/JP2022506956A5/ja
Pending legal-status Critical Current

Links

JP2021525115A 2018-11-09 2019-11-08 脂質ナノ粒子製剤 Pending JP2022506956A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862758088P 2018-11-09 2018-11-09
US62/758,088 2018-11-09
PCT/US2019/060582 WO2020097540A1 (en) 2018-11-09 2019-11-08 Lipid nanoparticle formulations

Publications (2)

Publication Number Publication Date
JP2022506956A JP2022506956A (ja) 2022-01-17
JP2022506956A5 true JP2022506956A5 (cg-RX-API-DMAC7.html) 2022-11-07

Family

ID=70611206

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525115A Pending JP2022506956A (ja) 2018-11-09 2019-11-08 脂質ナノ粒子製剤

Country Status (14)

Country Link
US (1) US12251470B2 (cg-RX-API-DMAC7.html)
EP (1) EP3877521A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022506956A (cg-RX-API-DMAC7.html)
KR (1) KR20210105889A (cg-RX-API-DMAC7.html)
CN (1) CN113286882A (cg-RX-API-DMAC7.html)
AU (1) AU2019376161B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021008982A2 (cg-RX-API-DMAC7.html)
EA (1) EA202191313A1 (cg-RX-API-DMAC7.html)
IL (1) IL282995B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005389A (cg-RX-API-DMAC7.html)
SG (1) SG11202104807YA (cg-RX-API-DMAC7.html)
UA (1) UA130104C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020097540A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103233B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CA3118559A1 (en) * 2018-11-09 2020-05-14 Arbutus Biopharma Corporation Lipid nanoparticle formulations
WO2021022108A2 (en) * 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2020355000A1 (en) 2019-09-23 2022-03-17 Sepia Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
CN114729376A (zh) 2019-09-23 2022-07-08 欧米茄治疗公司 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
CA3174708A1 (en) * 2020-03-04 2021-09-10 Verve Therapeutics, Inc. Compositions and methods for targeted rna delivery
WO2021183720A1 (en) 2020-03-11 2021-09-16 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
EP4132951A4 (en) 2020-04-09 2025-06-11 Verve Therapeutics, Inc. CHEMICALLY MODIFIED GENE EDITING GUIDE RNAS WITH CAS12B
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
CA3226019A1 (en) 2021-07-20 2023-01-26 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
EP4380576A4 (en) 2021-08-03 2026-04-29 Verve Therapeutics Inc RNA TARGETED COMPOSITIONS AND ADMINISTRATION METHODS
CA3132191A1 (en) * 2021-09-28 2023-03-28 Providence Therapeutics Holdings Inc. Compositions and methods for the prevention and/or treatment of covid-19
KR20230053998A (ko) 2021-10-15 2023-04-24 (주)지노믹트리 mRNA 발현을 위한 유전자 구조체
US20230302112A1 (en) * 2021-11-05 2023-09-28 Sanofi Respiratory synctial virus rna vaccine
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
CN118804743A (zh) * 2022-03-04 2024-10-18 益杰立科(上海)生物科技有限公司 靶向递送系统和方法
KR102796922B1 (ko) 2022-04-11 2025-04-15 연세대학교 원주산학협력단 mRNA 백신을 위한 양이온성 지질 나노입자
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
CA3256705A1 (en) * 2022-06-08 2023-12-14 Academia Sinica LIPIDS, THE NANOPARTICLES COMPRISING THEM, AND THEIR USES
JP2025535944A (ja) 2022-10-24 2025-10-30 エイジーエス・セラピューティクス・ソシエテ・パール・アクシオン・サンプリフィエ 微細藻類由来の細胞外小胞、鼻腔内投与時のそれらの生体内分布、及びそれらの使用
EP4716741A2 (en) 2023-05-23 2026-04-01 Flagship Labs 114, Inc. Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
EP4722368A1 (en) 2023-05-26 2026-04-08 Samsung Biologics Co., Ltd. Novel nucleic acid construct comprising poly(a) tail having secondary or tertiary structure and uses thereof
KR20250018367A (ko) 2023-07-28 2025-02-05 한국과학기술원 히스톤 코드 리더 도메인을 포함하는 폴리펩티드 및 이의 용도
KR20250064736A (ko) 2023-11-02 2025-05-12 (주)지노믹트리 방광암 예방 또는 치료용 조성물
AU2024409925A1 (en) 2023-12-26 2026-08-06 Emmune, Inc. Systems for nucleic acid transfer
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025210520A1 (en) * 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for inducing an immunological response
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN121265551A (zh) * 2024-07-02 2026-01-06 苏州星核迪赛生物技术有限公司 一种靶向肝实质细胞的核酸递送载体及其应用
CN121401231A (zh) * 2024-07-26 2026-01-27 深圳瑞吉生物科技有限公司 一种核酸脂质纳米载体及其制备方法与应用
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)
CN119732909A (zh) * 2024-12-24 2025-04-01 山东省药学科学院 一种具有促渗作用的纳米脂质体及其制备方法和应用
CN121287885A (zh) * 2025-12-11 2026-01-09 中国人民解放军军事科学院军事医学研究院 一种HGF mRNA脂质纳米颗粒(LNP)及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
EP1948674A4 (en) 2005-11-02 2009-02-04 Protiva Biotherapeutics Inc MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF
US9006191B2 (en) 2007-12-27 2015-04-14 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering RNA
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
WO2013158579A1 (en) 2012-04-19 2013-10-24 Merck Sharp & Dohme Corp. Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
WO2015011633A1 (en) 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
US10415037B2 (en) 2014-10-02 2019-09-17 Arbutus Biopharma Corporation Compositions and methods for silencing hepatitis B virus gene expression
EP3247328B1 (en) 2015-01-21 2026-01-07 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
AU2017379901B2 (en) * 2016-12-21 2024-02-15 Arbutus Biopharma Corporation Methods for ameliorating infusion reactions
CA3118559A1 (en) 2018-11-09 2020-05-14 Arbutus Biopharma Corporation Lipid nanoparticle formulations

Similar Documents

Publication Publication Date Title
JP2022506955A5 (cg-RX-API-DMAC7.html)
JP2023138984A (ja) Vegf-aポリペプチドをコードする改変rnaを送達するための脂質ナノ粒子
JP2022530018A5 (cg-RX-API-DMAC7.html)
KR102599712B1 (ko) C/EBP 알파 saRNA 조성물 및 사용 방법
US20240018519A1 (en) Stabilized saRNA Compositions and Methods of Use
US20180258429A1 (en) Sarna compositions and methods of use
JP2020022513A (ja) C/EBPα小分子活性化RNA組成物
JP2022532078A (ja) 皮膚及び創傷のための組成物並びにその使用の方法
Huang et al. An mTOR siRNA‐loaded spermidine/DNA tetrahedron nanoplatform with a synergistic anti‐inflammatory effect on acute lung injury
US20230313191A1 (en) Rna comprising secretomes and methods of their use
WO2023051822A1 (zh) 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2024045251A1 (zh) 一种治疗新生血管性视网膜疾病的小干扰rna及其dna四面体复合物
CN102784398B (zh) 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
ES2331835T3 (es) Oligonucleotidos antisentido capaces de inhibir la formacion de tubos capilares.
TW202305133A (zh) Tmem173 sarna組合物及其使用方法
CN120754284A (zh) 一种用于肝脏靶向联合递送CRISPR-Cas9系统和单链DNA修复模板的脂质纳米颗粒
JP2025538982A (ja) モヤモヤ病の予防または治療用組成物
US20240269248A1 (en) Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
WO2021115141A1 (zh) 一种抑制HTT基因表达的siRNA及其前体和应用
CN104922698B (zh) 人干细胞生长因子注射液及其制备方法
CN115998905B (zh) 治疗心衰的mRNA药物制剂及其制备方法与应用
WO2020208361A1 (en) Sirt1-sarna compositions and methods of use
CN119818705B (zh) 一种mRNA组合物及其应用
US20230364156A1 (en) Treating of neurological disorders using extracellular vesicles released by human induced pluripotent stem cell derived neural stem cells
TW202532107A (zh) 一種含核酸構建體的醫藥組成物及其醫藥用途